Home / ASX / Bidding war erupting at API

Bidding war erupting at API

ASX

The Wesfarmers Ltd (ASX: WES) and Woolworths Group Ltd (ASX: WOW) rivalry has been reignited today after Woolworths lobbed a $1.75 per share offer for Australian Pharmaceutical Industries Ltd (ASX: API).

  • Previously, Wesfarmers had made a binding offer of $1.55 per share for the pharmacy chain, which had been recommended by the API board.

    The deal looked largely complete until Friday’s shock announcement.

    Wesfarmers and Woolworths were formerly fierce competitors in the supermarket sector before Wesfarmer’s spun-off Coles Group Ltd (ASX: COL) in 2018.

    Battle for API heats up

    Woolworths $1.75 per share cash offer via a scheme of arrangement values the Priceline Pharmacy chain owner at $872 million.

    It’s a 20 cents per share, or a 12.9%, premium to Wesfarmers $1.55 per share proposal on November 8.

    Woolworths’s bid is still subject to due diligence, which it believes will take four weeks.

    On that timeline, a binding offer would be expected by mid-January 2022.

    Woolworths deal is subject to regulatory approval, a unanimous recommendation by the API board and an independent expert concluding the bid is in shareholders’ best interests.

    Wesfarmers still holds the ace

    Woolworths’ audacious bid for API still has one critical hurdle to jump through.

    Wesfarmers bought a 19.3% stake in API, therefore it holds a substantial share of voting power against any other proposal, including Woolworths.

    Subsequently, Woolworths would need to convince the remaining 80.7% of API’s shareholders to vote in its favour.

    A scheme of arrangement requires at least 75% of shareholder votes. Therefore, the supermarket giant would need at least 92% of API’s shareholders on its side should Wesfarmers vote against the deal – no easy task.

    Woolworths has said it’s open to exploring alternative control structures, such as a takeover bid with acceptance of just 50.1%.

    Nonetheless, Wesfarmers won’t roll over easily given it’s already fended off a competing offer from Sigma Healthcare Ltd (ASX: SIG).

    The conglomerate has the right to match Woolworths’ bid, which would make for a fierce standoff.

    API response

    The API board has allowed Woolworths to undertake due diligence as it believes the offer is superior to Wesfarmers:

    “…the API Board considers that the Woolworths Proposal is reasonably capable of being valued, implemented and completed in accordance with its terms, and, if completed substantially in accordance with its terms, be more favourable to API shareholders as a whole than the Wesfarmers Scheme”

    My take

    In what is generally a quiet month for corporate Australia, Woolworths, Wesfarmers and its bankers will be working feverishly to win control for API.

    I’d expect Wesfarmers to match the bid, and then force Woolworths either to raise, or walk away.

    Either way, the battle for API looks to be heating up again.

    Information warning: The information in this article was published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate




    Print Article

    Related
    Flight Centre hits bumpy patch – but longer-term outlook smoother

    A mild warning to the market from this global travel group in October had skittish investors bailing out. Those who held their nerve could enjoy a higher payout and share price if the travel industry picks up in 2025.

    Jamie Nemtsas | 18th Dec 2024 | More
    Raiz’s quarterly numbers finally start to excite the market

    The micro fund manager reported a solid performance with increasing funds under management, revenue and active customers. On the sharemarket, investors have been finding some appetite for this stock, but it’s a far cry from the buying frenzy that took it to $2 in 2021.

    Jamie Nemtsas | 18th Dec 2024 | More
    Private health system’s woes take toll on Ramsay share price

    Australia’s largest private healthcare provider is growing turnover, making a profit and rewarding shareholders. It’s still failing to impress a sharemarket that is constantly being reminded of the sector’s poor health.

    Jamie Nemtsas | 11th Dec 2024 | More
    Popular